HC Wainwright reaffirmed their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q3 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.21) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.18) EPS.
A number of other analysts have also weighed in on the company. Ascendiant Capital Markets raised their target price on Atossa Therapeutics from $6.00 to $6.25 and gave the company a buy rating in a research note on Thursday, June 6th. StockNews.com upgraded shares of Atossa Therapeutics from a sell rating to a hold rating in a research report on Tuesday, May 14th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Atossa Therapeutics in a research report on Thursday, June 20th.
View Our Latest Report on ATOS
Atossa Therapeutics Trading Up 3.2 %
Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, equities research analysts predict that Atossa Therapeutics will post -0.23 EPS for the current year.
Hedge Funds Weigh In On Atossa Therapeutics
Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after purchasing an additional 78,269 shares during the period. Renaissance Technologies LLC raised its stake in shares of Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after buying an additional 164,540 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after buying an additional 399,041 shares during the last quarter. Rhumbline Advisers acquired a new position in Atossa Therapeutics in the second quarter valued at approximately $161,000. Finally, Virtu Financial LLC bought a new position in Atossa Therapeutics in the first quarter valued at approximately $151,000. Institutional investors own 12.74% of the company’s stock.
Atossa Therapeutics Company Profile
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Featured Articles
- Five stocks we like better than Atossa Therapeutics
- Investing in the High PE Growth Stocks
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Jeff Brown’s Exegesis AI Stock Picks
- The 3 Best Fintech Stocks to Buy Now
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.